
Opinion|Videos|February 14, 2025 (Updated: January 31, 2025)
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
This segment explores Dr. Rossi's clinical experience with cilta-cel as a second-line therapy, focusing on its efficacy and quality-of-life benefits across diverse patient populations.
Advertisement
Video content above is prompted by the following:
- Can you share your experience with cilta-cel as a second-line therapy?
- What advantages in terms of efficacy and quality of life have you noted across various patient populations?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
In Vivo CAR Engineering and the Next Phase of Cellular Immunotherapy
2
FDA Delays Decision on Subcutaneous Isatuximab in Multiple Myeloma
3
TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML
4
3 Things You Should Know About TROP2-Directed Antibody-Drug Conjugates in the Frontline Treatment of Metastatic Triple-Negative Breast Cancer
5






















































